REGN - Regeneron Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Tarrytown,
United States
Type: Equity
REGN price evolution
REGN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1920.7 | $2602 | $2730 | |
| Short term investments | $7888.3 | $7917.5 | $8114.8 | |
| Net receivables | $6107.1 | $5717.1 | $5222.2 | $5667.3 |
| Inventory | $3018 | $2873.6 | $2714.9 | $2580.5 |
| Total current assets | $19333.6 | $19081.6 | $18871.5 | $19479.2 |
| Long term investments | $7722.4 | $6978.8 | $5396.5 | |
| Property, plant & equipment | $4439.2 | $4305.9 | $4225.5 | $4146.4 |
| Goodwill & intangible assets | $1102.2 | $1058.7 | $1038.6 | |
| Total noncurrent assets | $17005.2 | $15498.1 | $13601 | |
| Total investments | $15610.7 | $14896.3 | $13511.3 | |
| Total assets | $37441.9 | $36086.8 | $34369.6 | $33080.2 |
| Current liabilities | ||||
| Accounts payable | $497.3 | $561.7 | $671.3 | $606.6 |
| Deferred revenue | $791.6 | $702.5 | $585.6 | |
| Short long term debt | ||||
| Total current liabilities | $3661 | $3508.6 | $3580.9 | $3423.4 |
| Long term debt | $2704 | $2703.6 | $2703.3 | $2702.9 |
| Total noncurrent liabilities | $4372.4 | $3797.6 | $3683.7 | |
| Total debt | $2703.6 | $2703.3 | $2702.9 | |
| Total liabilities | $8116 | $7881 | $7378.5 | $7107.1 |
| Shareholders' equity | ||||
| Retained earnings | $30755.2 | $29414.6 | $27982.3 | $27260.3 |
| Other shareholder equity | $60.2 | -$69.9 | -$77.2 | -$80.9 |
| Total shareholder equity | $28205.8 | $26991.1 | $25973.1 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2730 | $3105.9 | $2885.6 | $2193.7 |
| Short term investments | $8114.8 | $4636.4 | $2809.1 | $1393.3 |
| Net receivables | $5667.3 | $5328.7 | $6036.5 | $4114.7 |
| Inventory | $2580.5 | $2401.9 | $1951.3 | $1916.6 |
| Total current assets | $19479.2 | $22064.7 | $14014.9 | $9779.1 |
| Long term investments | $5396.5 | $6591.8 | $6838 | $3135.6 |
| Property, plant & equipment | $4146.4 | $3763 | $3482.2 | $3221.6 |
| Goodwill & intangible assets | $1038.6 | $915.5 | ||
| Total noncurrent assets | $13601 | $13330.4 | $11419.9 | $7384.2 |
| Total investments | $13511.3 | $11228.2 | $9647.1 | $4528.9 |
| Total assets | $33080.2 | $29214.5 | $25434.8 | $17163.3 |
| Current liabilities | ||||
| Accounts payable | $606.6 | $3301.4 | $564 | $475.5 |
| Deferred revenue | $585.6 | $547.7 | $515.3 | $635.5 |
| Short long term debt | $719.7 | |||
| Total current liabilities | $3423.4 | $3849.1 | $3932.5 | $2697.4 |
| Long term debt | $2702.9 | $2701.4 | $1980 | $2695.7 |
| Total noncurrent liabilities | $3683.7 | $3409.2 | $2733.5 | $3440.6 |
| Total debt | $2702.9 | $2701.4 | $2699.7 | $2695.7 |
| Total liabilities | $7107.1 | $6550.5 | $6666 | $6138 |
| Shareholders' equity | ||||
| Retained earnings | $27260.3 | $23306.7 | $18968.3 | $10893 |
| Other shareholder equity | -$80.9 | $22664 | -$26.2 | $29.3 |
| Total shareholder equity | $25973.1 | $22664 | $18768.8 | $11025.3 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3720.7 | $3547.1 | $3145 | $3434.3 |
| Cost of revenue | $480.2 | $433.8 | $517 | |
| Gross Profit | $3229.6 | $3066.9 | $2711.2 | $2917.3 |
| Operating activities | ||||
| Research & development | $1200 | $1248.4 | $1177.2 | |
| Selling, general & administrative | $758.8 | $689 | $737.7 | |
| Total operating expenses | $1993.9 | $1997.3 | $1959.8 | $1944.4 |
| Operating income | $1069.6 | $751.4 | $972.9 | |
| Income from continuing operations | ||||
| EBIT | $1642.9 | $716.8 | $1165.9 | |
| Income tax expense | $152.4 | $195.8 | -$21.3 | -$12 |
| Interest expense | $308.1 | $14.8 | $16.1 | $18.3 |
| Net income | ||||
| Net income | $1340.6 | $1432.3 | $722 | $1159.6 |
| Income (for common shares) | $1432.3 | $722 | $1159.6 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $13117.2 | $12172.9 | $16071.7 | $8497.1 |
| Cost of revenue | $1815.8 | $1560.4 | $2437.5 | $1119.9 |
| Gross Profit | $11301.4 | $10612.5 | $13634.2 | $7377.2 |
| Operating activities | ||||
| Research & development | $4439 | $3592.5 | $2908.1 | $2735 |
| Selling, general & administrative | $2631.3 | $2115.9 | $1824.9 | $1346 |
| Total operating expenses | $7254.3 | $5873.6 | $4687.4 | $3800.6 |
| Operating income | $4047.1 | $4738.9 | $8946.8 | $3576.6 |
| Income from continuing operations | ||||
| EBIT | $4272.3 | $4918.2 | $9383.1 | $3867.3 |
| Income tax expense | $245.7 | $520.4 | $1250.5 | $297.2 |
| Interest expense | $73 | $59.4 | $57.3 | $56.9 |
| Net income | ||||
| Net income | $3953.6 | $4338.4 | $8075.3 | $3513.2 |
| Income (for common shares) | $3953.6 | $4338.4 | $8075.3 | $3513.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $1432.3 | $722 | $1159.6 | |
| Operating activities | ||||
| Depreciation | $120.7 | $114.1 | $113 | |
| Business acquisitions & disposals | -$35.4 | -$27.9 | -$65.9 | |
| Stock-based compensation | $223.2 | $230.1 | $240.4 | |
| Total cash flows from operations | $354 | $1512.5 | $1089.7 | |
| Investing activities | ||||
| Capital expenditures | -$160.4 | -$133.9 | -$251.4 | |
| Investments | -$361.4 | -$1525.3 | $251.1 | |
| Total cash flows from investing | -$2818.7 | -$557.2 | -$1687.1 | -$66.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$478.1 | $47.1 | -$446.1 | |
| Net borrowings | ||||
| Total cash flows from financing | -$1065 | -$478.1 | $47.1 | -$446.1 |
| Effect of exchange rate | -$0.3 | -$0.5 | $0.2 | |
| Change in cash and equivalents | -$726 | -$681.6 | -$128 | $577.6 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $3953.6 | $4338.4 | $8075.3 | $3513.2 |
| Operating activities | ||||
| Depreciation | $421 | $341.4 | $286.2 | $235.9 |
| Business acquisitions & disposals | -$262.7 | -$1257.1 | ||
| Stock-based compensation | $885 | $725 | $601.7 | $432 |
| Total cash flows from operations | $4594 | $5014.9 | $7081.3 | $2618.1 |
| Investing activities | ||||
| Capital expenditures | -$718.6 | -$590.1 | -$551.9 | -$614.6 |
| Investments | -$2203.8 | -$1937.4 | -$4832.8 | $544 |
| Total cash flows from investing | -$3185.1 | -$3784.6 | -$5384.7 | -$70.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$1790.1 | -$1009 | -$1005.8 | -$3952.4 |
| Net borrowings | $1981.9 | |||
| Total cash flows from financing | -$1790.1 | -$1009 | -$1005.8 | -$1970.5 |
| Effect of exchange rate | -$0.4 | |||
| Change in cash and equivalents | -$381.6 | $221.3 | $690.8 | $577 |
News
Fundamentals
| Market cap | $81.97B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 110.10M |
| Revenue | $13.85B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $4.65B |
| Revenue Q/Q | 10.65% |
| Revenue Y/Y | 5.72% |
| P/E ratio | 17.61 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 5.92 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $42.28 |
|---|---|
| ROA | 13.21% |
| ROE | N/A |
| Debt/Equity | 0.27 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.28 |
| Quick ratio | 4.46 |